XV

Xvivo Perfusion ABSTO Xvivo Perfusion Stock Report

Last reporting period 30 Sep, 2024

Updated 11 Nov, 2024

Last price

Market cap $B

1.556

Small

Exchange

XSTO - Nasdaq STOCKHOLM AB

XVIVO.ST Stock Analysis

XV

Neutral

Based on Eyestock quantitative analysis, XVIVO.ST`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

77/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

281.6 %

Greatly undervalued

Market cap $B

1.556

Dividend yield

Shares outstanding

29.562 B

Xvivo Perfusion AB is a medical technology company. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2012-10-08. The firm operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The firm markets its products in Europe, Asia, Middle East, and North & South America.

View Section: Eyestock Rating